<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管出版物</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff= 20 231109170741&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;fc =20230708114047<description>心血管亮点：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20231109170741&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;fc=20230708114047" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 11 月 9 日星期四 22:07:44 +0000</lastbuilddate><pubDate> Thu, 09 Nov 2023 06:00:00 -0500</pubDate><ttl> 120</ttl><item><title> 2023 年心肺复苏和急诊心血管护理科学国际共识及治疗建议：基本生命支持、高级生命支持、儿科生命支持、新生儿生命支持、教育、实施和团队以及急救工作组摘要</title><link/>https://pubmed.ncbi.nlm.nih.gov/37942682/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231109170741&amp;v=2.17.9.post6+86293ac<description>国际复苏联络委员会对新的、同行评审的、已发表的心肺复苏和急救科学进行持续审查。《治疗建议科学共识草案》全年在线发布，本年度摘要提供了更简洁的版本今年所有工作组就治疗建议达成的最终科学共识。今年系统评价涉及的主题包括复苏…… </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 11 月 9 日。doi：10.1161/CIR.0000000000001179。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">国际复苏联络委员会对新的、同行评审的、已发表的心肺复苏和急救科学进行持续审查。《治疗建议科学共识草案》全年在线发布，本年度摘要提供了更简洁的版本今年所有工作组的治疗建议最终科学共识。今年系统评价涉及的主题包括溺水心脏骤停的复苏、成人和儿童的体外心肺复苏、心脏骤停期间的钙、双序贯除颤、心脏骤停后的神经预后成人和儿童的逮捕、早产后维持正常体温、新生儿诊断的心率监测方法、新生儿呼出二氧化碳的检测、成人复苏过程中家人在场以及逐步进行复苏技能培训。来自 6 International 的成员复苏联络委员会工作组使用建议评估分级、制定和评估标准对证据质量进行了评估、讨论和辩论，其声明包括共识治疗建议。对工作组审议情况的见解提供于论证和证据决策框架亮点部分。此外，工作组列出了进一步研究的优先知识差距。通过范围审查和证据更新解决了其他主题。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37942682/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231109170741&v=2.17.9.post6+86293ac">37942682</a> | DOI： <a href=https://doi.org/10.1161/CIR.0000000000001179>10.1161/CIR.0000000000001179</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37942682</guid><pubDate> Thu, 09 Nov 2023 06:00:00 -0500</pubDate><dc:creator>凯瑟琳·伯格</dc:creator><dc:creator>珍妮特·E·布雷</dc:creator><dc:creator>吴基昌</dc:creator><dc:creator>海伦·G·莉莉</dc:creator><dc:creator>罗伯特·格雷夫</dc:creator><dc:creator>杰斯汀·卡尔森</dc:creator><dc:creator>彼得·T·莫利</dc:creator><dc:creator>伊恩·R·德伦南</dc:creator><dc:creator>迈克尔·史密斯</dc:creator><dc:creator>巴纳比·R·斯科菲尔德</dc:creator><dc:creator>加里·韦纳</dc:creator><dc:creator>郑少秋</dc:creator><dc:creator>特蕾莎·贾尔夫</dc:creator><dc:creator>克里斯蒂安·阿贝莱拉斯-戈麦斯</dc:creator><dc:creator>贾森·阿克沃斯</dc:creator><dc:creator>拉尔斯·W·安德森</dc:creator><dc:creator>黛安·L·阿特金斯</dc:creator><dc:creator>大卫·C·贝里</dc:creator><dc:creator>法尔汗·班吉</dc:creator><dc:creator>约斯特·比伦斯</dc:creator><dc:creator>托马斯·比当古·库托</dc:creator><dc:creator>维尔博拉</dc:creator><dc:creator>贝恩德·W·博蒂格</dc:creator><dc:creator>理查德·布拉德利</dc:creator><dc:creator>扬·布雷克沃尔特</dc:creator><dc:creator>帕斯卡·卡桑</dc:creator><dc:creator>张伟天</dc:creator><dc:creator>内森·P·查尔顿</dc:creator><dc:creator>郑成菲尔</dc:creator><dc:creator>朱莉·康斯丁</dc:creator><dc:creator>丹妮拉·T·科斯塔-诺布雷</dc:creator><dc:creator>基思·库珀</dc:creator><dc:creator>凯蒂·丹蒂</dc:creator><dc:creator>维哈拉·达萨纳亚克</dc:creator><dc:creator>彼得·G·戴维斯</dc:creator><dc:creator>詹妮弗·道森</dc:creator><dc:creator>玛丽亚·费尔南达·德·阿尔梅达</dc:creator><dc:creator>艾伦·R·德·卡昂</dc:creator><dc:creator>查尔斯·D·迪肯</dc:creator><dc:creator>布里奇特·迪克</dc:creator><dc:creator>马修·J·杜马</dc:creator><dc:creator>凯瑟琳·伊斯特伍德</dc:creator><dc:creator>瓦利德·埃尔-纳加尔</dc:creator><dc:creator>豪尔赫·G·法布尔</dc:creator><dc:creator>乔·福克斯</dc:creator><dc:creator>尼诺·菲亚科</dc:creator><dc:creator>朱迪思·C·芬恩</dc:creator><dc:creator>古斯塔沃·E·弗洛雷斯</dc:creator><dc:creator>伊丽莎白·E·福利亚</dc:creator><dc:creator>弗雷德里克·福克</dc:creator><dc:creator>伊莱恩·吉尔福伊尔</dc:creator><dc:creator>克雷格·古尔斯比</dc:creator><dc:creator>阿斯格·格兰费尔特</dc:creator><dc:creator>安妮·玛丽·盖尔盖里安</dc:creator><dc:creator>露丝金斯堡</dc:creator><dc:creator>畠中哲夫</dc:creator><dc:creator>凯伦·G·赫希</dc:creator><dc:creator>马蒂亚斯·霍姆伯格</dc:creator><dc:creator>细野茂治</dc:creator><dc:creator>谢明如</dc:creator><dc:creator>许欣迪</dc:creator><dc:creator>池山贵成</dc:creator><dc:creator>谏山哲也</dc:creator><dc:creator>尼古拉斯·约翰逊</dc:creator><dc:creator>维沙尔·卡帕迪亚</dc:creator><dc:creator>曼迪拉·达里帕·卡瓦卡米</dc:creator><dc:creator>金韩石</dc:creator><dc:creator>莫妮卡·E·克莱曼</dc:creator><dc:creator>大卫·A·克洛克</dc:creator><dc:creator>彼得·库登丘克</dc:creator><dc:creator>艾米·库勒</dc:creator><dc:creator>黑泽宏</dc:creator><dc:creator>安东尼·T·拉吉纳</dc:creator><dc:creator>卡斯帕·G·劳里森</dc:creator><dc:creator>埃里克·J·拉沃纳斯</dc:creator><dc:creator>亨利·C·李</dc:creator><dc:creator>林依群</dc:creator><dc:creator>安德鲁·S·洛基</dc:creator><dc:creator>芬利·麦克尼尔</dc:creator><dc:creator>伊恩·K·麦科诺奇</dc:creator><dc:creator>R约翰·马达尔</dc:creator><dc:creator>卡罗莱纳州马耳他汉森</dc:creator><dc:creator>西沃恩·马斯特森</dc:creator><dc:creator>松山佑</dc:creator><dc:creator>克里斯托弗·麦金莱</dc:creator><dc:creator>丹尼尔·梅兰</dc:creator><dc:creator>维克斯·蒙纳利</dc:creator><dc:creator>维奈纳德卡尼</dc:creator><dc:creator>菲尔多斯·L·纳夸</dc:creator><dc:creator>凯文·J·内森</dc:creator><dc:creator>齐亚德·内梅</dc:creator><dc:creator>迈克尔·内梅斯</dc:creator><dc:creator>罗伯特·W·诺伊马尔</dc:creator><dc:creator>托尼娅·尼克尔森</dc:creator><dc:creator>尼古拉斯·尼古拉斯</dc:creator><dc:creator>西山千花</dc:creator><dc:creator>典井达也</dc:creator><dc:creator>加布里埃尔·A·纳索尔</dc:creator><dc:creator>大下慎一郎</dc:creator><dc:creator>特里萨·M·奥拉斯芬根</dc:creator><dc:creator>王永光</dc:creator><dc:creator>亚伦·M·奥金</dc:creator><dc:creator>迈克尔·J·帕尔</dc:creator><dc:creator>凯瑟琳·帕托卡</dc:creator><dc:creator>加文·帕金斯</dc:creator><dc:creator>杰弗里·帕尔曼</dc:creator><dc:creator>雅各夫·拉比</dc:creator><dc:creator>詹姆斯·雷特</dc:creator><dc:creator>沙利尼·拉马钱德兰</dc:creator><dc:creator>维拉加万 V 拉马斯瓦米</dc:creator><dc:creator>蒂亚·T·雷蒙德</dc:creator><dc:creator>阿米莉亚·G·雷斯</dc:creator><dc:creator>约书亚·C·雷诺兹</dc:creator><dc:creator>朱塞佩·里斯塔尼奥</dc:creator><dc:creator>安东尼奥·罗德里格斯·努涅斯</dc:creator><dc:creator>查尔斯·C·罗尔</dc:creator><dc:creator>马里奥·吕迪格</dc:creator><dc:creator>坂本哲也</dc:creator><dc:creator>克劳迪奥·桑德罗尼</dc:creator><dc:creator>泰勒·L·索耶</dc:creator><dc:creator>史蒂夫·M·谢克斯奈德</dc:creator><dc:creator>格奥尔格·M·施莫尔泽</dc:creator><dc:creator>塞巴斯蒂安·施瑙贝尔特</dc:creator><dc:creator>费德里科·塞梅拉罗</dc:creator><dc:creator>尤尼斯·M·辛格特里</dc:creator><dc:creator>马库斯·B·斯克里瓦尔斯</dc:creator><dc:creator>克里斯托弗·M·史密斯</dc:creator><dc:creator>贾斯米特·索尔</dc:creator><dc:creator>威廉·斯塔森</dc:creator><dc:creator>杉浦贵宏</dc:creator><dc:creator>珍妮丝·蒂森</dc:creator><dc:creator>亚历克西斯·托普吉安</dc:creator><dc:creator>丹尼尔·特雷维萨努托</dc:creator><dc:creator>克里斯蒂安·瓦扬古</dc:creator><dc:creator>迈拉·H·威科夫</dc:creator><dc:creator>乔纳森·P·威利</dc:creator><dc:creator>杨志伟</dc:creator><dc:creator>杨欣宜</dc:creator><dc:creator>卡罗琳·M·泽洛普</dc:creator><dc:creator>大卫·齐德曼</dc:creator><dc:creator>杰里·P·诺兰</dc:creator><dc:creator>合作者</dc:creator><dc:date>2023-11-09</dc:date><dc:source>循环</dc:source><dc:title>2023 年心肺复苏和急诊心血管护理科学国际共识及治疗建议：基本生命支持、高级生命支持、儿科生命支持、新生儿生命支持、教育、实施和团队以及急救工作组摘要</dc:title><dc:identifier>下午:37942682</dc:identifier><dc:identifier>号码：10.1161/CIR.0000000000001179</dc:identifier></item><item><title>趋化因子受体 3 自身抗体可预测心血管风险</title><link/>https://pubmed.ncbi.nlm.nih.gov/37941454/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231109170741&amp;v=2.17.9.post6+86293ac<description>结论：在无自身免疫性疾病的个体中，抗 CXCR3 aAb 丰富，与 CV 终末器官损伤相关，并可预测全因死亡以及心脏发病率和死亡率以及实验性动脉粥样硬化的加速。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 11 月 6 日：ehad666。doi：10.1093/eurheartj/ehad666。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：慢性炎症和自身免疫导致心血管（CV）疾病。最近，针对 CXC 基序趋化因子受体 3（CXCR3）（一种在动脉粥样硬化中起关键作用的 G 蛋白偶联受体）的自身抗体（aAb）已被开发出来。抗 CXCR3 aAb 对 CV 风险和疾病的作用尚不清楚。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：通过市售酶联免疫吸附测定对基于人群的古腾堡健康研究的 5000 名参与者（可用性：97.1%）的抗 CXCR3 aAb 进行定量，并进行广泛的临床表型分析。进行回归分析以确定抗 CXCR3 aAb 的决定因素。 CXCR3 aAb 和与临床结果的相关性（即全因死亡率、心源性死亡、心力衰竭和主要不良心脏事件，包括冠状动脉疾病、心肌梗塞和心源性死亡）。最后，CXCR3 免疫和 aAb 被动转移在 ApoE(-/-) 小鼠中进行临床前验证。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：排除患有自身免疫性疾病、免疫调节药物、急性感染和癌症病史的个体后，分析样本包括 4195 名个体（48% 女性，平均年龄 55.5 ± 11 岁）。年龄、性别、肾功能和传统治疗的独立性CV 危险因素，抗 CXCR3 aAb 浓度的增加转化为更高的内膜中层厚度、左心室质量和 N 末端 B 型利钠肽前体。根据年龄和性别进行调整，抗 CXCR3 aAb 高于预测的第 75 个百分位全因死亡[风险比 (HR)（95% 置信区间）1.25 (1.02, 1.52), P = .029]，由过高的心脏死亡率驱动 [HR 2.51 (1.21, 5.22), P = .014]。主要不良心脏事件的风险较高 [HR 1.42 (1.0, 2.0), P = .05]，同时发生心力衰竭的风险也增加 [抗 CXCR3 aAb 增加的每标准差 HR：1.26 (1.02, 1.56) , P = .03] 可能有助于这一观察。靶向蛋白质组学揭示了抗 CXCR3 aAb 的分子特征，反映了与正在进行的 T 辅助细胞 1 反应相关的免疫细胞激活和细胞因子-细胞因子受体相互作用。最后，ApoE(-/- ）与未免疫对照相比，针对 CXCR3 进行免疫的小鼠表现出抗 CXCR3 aAb 增加，并显示出更高的动脉粥样硬化负担，这与被动转移模型中抗 CXCR3 aAb 的浓度相关。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：在无自身免疫性疾病的个体中，抗 CXCR3 aAb 丰富，与 CV 终末器官损伤相关，并可预测全因死亡以及心脏发病率和死亡率以及实验性动脉粥样硬化的加速。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37941454/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231109170741&v=2.17.9.post6+86293ac">37941454</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad666>10.1093/eurheartj/ehad666</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37941454</guid><pubDate> Thu, 09 Nov 2023 06:00:00 -0500</pubDate><dc:creator>费利克斯·穆勒</dc:creator><dc:creator>祖海尔·阿赫拉鲁</dc:creator><dc:creator>汉娜·格拉肖夫</dc:creator><dc:creator>马克·W·海多恩</dc:creator><dc:creator>詹斯·Y·汉里奇</dc:creator><dc:creator>劳伦斯·约翰逊</dc:creator><dc:creator>雷杜安·阿赫拉鲁</dc:creator><dc:creator>托拜厄斯·赖因伯格</dc:creator><dc:creator>安德烈亚斯·舒尔茨</dc:creator><dc:creator>文森特十凯特</dc:creator><dc:creator>亚历杭德罗·帕拉雷斯·罗伯斯</dc:creator><dc:creator>托马斯·科克</dc:creator><dc:creator>史蒂芬·拉普</dc:creator><dc:creator>塔尼娅·兰格</dc:creator><dc:creator>卢卡斯·布拉查切克</dc:creator><dc:creator>芬恩·吕伯</dc:creator><dc:creator>珍妮特·埃德曼</dc:creator><dc:creator>哈拉尔德·海德克</dc:creator><dc:creator>凯·舒尔茨-福斯特</dc:creator><dc:creator>拉尔夫·德钦德</dc:creator><dc:creator>卡尔·J·拉克纳</dc:creator><dc:creator>诺伯特·菲佛</dc:creator><dc:creator>贾斯明·加米·克拉罗迪</dc:creator><dc:creator>奥利弗·塔舍尔</dc:creator><dc:creator>安德烈亚斯·施瓦廷</dc:creator><dc:creator>康斯坦丁·斯特劳赫</dc:creator><dc:creator>托马斯·明泽尔</dc:creator><dc:creator>于尔根·H·普罗查斯卡</dc:creator><dc:creator>加布里埃拉·里梅卡斯坦</dc:creator><dc:creator>菲利普·S·怀尔德</dc:creator><dc:date>2023-11-09</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>趋化因子受体 3 自身抗体可预测心血管风险</dc:title><dc:identifier>下午:37941454</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad666</dc:identifier></item><item><title>早期活检和结果证明暴发性心肌炎</title><link/>https://pubmed.ncbi.nlm.nih.gov/37941449/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231109170741&amp;v=2.17.9.post6+86293ac<description>结论：心内膜心肌活检应广泛、及时地应用于临床疑似暴发性心肌炎入住重症监护病房的患者。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 11 月 6 日：ehad707。doi：10.1093/eurheartj/ehad707。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：虽然建议对暴发性心肌炎成年患者进行心内膜心肌活检（EMB），但其时机的临床影响仍不清楚。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：收集了全球 15 个国家 36 个三级中心重症监护室收治的 419 名临床疑似暴发性心肌炎成人患者的数据。其中 210 名患者（50%）通过 EMB（n = 183）通过组织学证实了心肌炎的诊断。 , 44%) 或通过尸检/移植心脏检查 (n = 27, 6%)，以及临床怀疑的心脏磁共振成像在 96 名 (23%) 患者中得到证实。主要结局是无心脏移植 (HTx) 或左存活特别比较了早期 EMB（入住重症监护病房后 2 天内，n = 103）和延迟 EMB（n = 80）患者 1 年时心室辅助装置（LVAD）的情况。进行了倾向评分加权分析来控制对于混杂因素。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：入院时的中位年龄为 40 (29-52) 岁，322 例 (77%) 患者接受了临时机械循环支持。总共 273 例 (65%) 患者在未接受 HTx/LVAD 的情况下存活。早期和延迟 EMB 患者（70% vs. 49%，P = .004）。倾向评分加权后，早期 EMB 组与延迟 EMB 组在无 HTx/LVAD 生存率方面仍存在显着差异（63% vs. . . 40%, P = .021). 此外，早期 EMB 与 1 年死亡率或 HTx/LVAD 较低独立相关（比值比为 0.44；95% 置信区间：0.22-0.86；P = .016 ）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：心内膜心肌活检应广泛、及时地应用于临床疑似暴发性心肌炎入住重症监护病房的患者。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37941449/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231109170741&v=2.17.9.post6+86293ac">37941449</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad707>10.1093/eurheartj/ehad707</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37941449</guid><pubDate> Thu, 09 Nov 2023 06:00:00 -0500</pubDate><dc:creator>黄佛伦</dc:creator><dc:creator>恩里科·阿米拉蒂</dc:creator><dc:creator>波纳雅大君</dc:creator><dc:creator>圣地亚哥·蒙特罗</dc:creator><dc:creator>维克多·兰博</dc:creator><dc:creator>达里尔·艾布拉姆斯</dc:creator><dc:creator>纪尧姆·勒布雷顿</dc:creator><dc:creator>文森特·佩莱格里诺</dc:creator><dc:creator>约书亚·伊勒</dc:creator><dc:creator>毛里齐奥·波蒂罗利</dc:creator><dc:creator>罗曼·佩尔西尼</dc:creator><dc:creator>玛丽莎·伊莎贝尔·巴里奥努埃沃-桑切斯</dc:creator><dc:creator>阿尔伯特·阿里萨-索尔</dc:creator><dc:creator>吴宝莲</dc:creator><dc:creator>冼伟正</dc:creator><dc:creator>拉杰·艾尔</dc:creator><dc:creator>赫尔根·布舍尔</dc:creator><dc:creator>斯里曼·贝莱德</dc:creator><dc:creator>克莱门特·德尔马斯</dc:creator><dc:creator>丽塔·费雷拉</dc:creator><dc:creator>罗伯托·龙康阿尔伯克基</dc:creator><dc:creator>特蕾莎·洛佩斯-索布里诺</dc:creator><dc:creator>杰伦·J·H·邦吉</dc:creator><dc:creator>克里斯托夫·菲瑟</dc:creator><dc:creator>纪尧姆·弗兰奇诺</dc:creator><dc:creator>杰米·麦卡尼</dc:creator><dc:creator>大下真一郎</dc:creator><dc:creator>亚历山德罗·西奥尼斯</dc:creator><dc:creator>弗朗西斯科·何塞·埃尔南德斯-佩雷斯</dc:creator><dc:creator>爱德华多·巴尔吉·卡瓦列罗</dc:creator><dc:creator>马丁·巴利克</dc:creator><dc:creator>恩里克·穆利亚</dc:creator><dc:creator>朴成勋</dc:creator><dc:creator>德克·W·唐克</dc:creator><dc:creator>比阿特丽斯·波拉尔</dc:creator><dc:creator>纳迪亚·艾萨维</dc:creator><dc:creator>阿曼德·梅孔措·德萨普</dc:creator><dc:creator>弗吉尼亚布尔戈斯</dc:creator><dc:creator>马蒂厄·莱苏海蒂尔</dc:creator><dc:creator>贾斯汀·弗里德</dc:creator><dc:creator>郑在承</dc:creator><dc:creator>桑德拉·罗西洛</dc:creator><dc:creator>文森特谢勒</dc:creator><dc:creator>萨阿德·恩塞尔</dc:creator><dc:creator>哈德里安·温斯泽夫斯基</dc:creator><dc:creator>巴勃罗·豪尔赫·佩雷斯</dc:creator><dc:creator>安托万·金蒙</dc:creator><dc:creator>罗德里戈·迪亚兹</dc:creator><dc:creator>阿兰·库姆斯</dc:creator><dc:creator>马蒂厄·施密特</dc:creator><dc:creator>满月研究小组</dc:creator><dc:date>2023-11-09</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>早期活检和结果证明暴发性心肌炎</dc:title><dc:identifier>下午：37941449</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad707</dc:identifier></item><item><title> Emery-Dreifuss 肌营养不良症：仔细观察心脏并发症</title><link/>https://pubmed.ncbi.nlm.nih.gov/37941127/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231109170741&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 11 月 6 日：ehad735。doi：10.1093/eurheartj/ehad735。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37941127/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231109170741&v=2.17.9.post6+86293ac">37941127</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad735>10.1093/eurheartj/ehad735</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37941127</guid><pubDate> Thu, 09 Nov 2023 06:00:00 -0500</pubDate><dc:creator>达莉亚·克拉马连科</dc:creator><dc:creator>罗迪·沃尔什</dc:creator><dc:date>2023-11-09</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>Emery-Dreifuss 肌营养不良症：仔细观察心脏并发症</dc:title><dc:identifier>下午：37941127</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad735</dc:identifier></item><item><title>五个简单的部分仅占心血管疾病和全因死亡事件的一小部分</title><link/>https://pubmed.ncbi.nlm.nih.gov/37941126/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231109170741&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 11 月 6 日：ehad731。doi：10.1093/eurheartj/ehad731。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37941126/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231109170741&v=2.17.9.post6+86293ac">37941126</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad731>10.1093/eurheartj/ehad731</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37941126</guid><pubDate> Thu, 09 Nov 2023 06:00:00 -0500</pubDate><dc:creator>乔凡娜·柳佐</dc:creator><dc:creator>卡罗·帕特罗诺</dc:creator><dc:date>2023-11-09</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>五个简单的部分仅占心血管疾病和全因死亡事件的一小部分</dc:title><dc:identifier>下午：37941126</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad731</dc:identifier></item><item><title>回复：C 反应蛋白与已确诊心血管疾病患者的心力衰竭：来自英国生物银行的证据</title><link/>https://pubmed.ncbi.nlm.nih.gov/37940237/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231109170741&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 11 月 14 日；82(20):e193.doi:10.1016/j.jacc.2023.09.803。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37940237/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231109170741&v=2.17.9.post6+86293ac">37940237</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.09.803>10.1016/j.jacc.2023.09.803</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37940237</guid><pubDate> Wed, 08 Nov 2023 06:00:00 -0500</pubDate><dc:creator>帕斯卡·M·伯格</dc:creator><dc:creator>弗兰克·L·J·维瑟伦</dc:creator><dc:creator>詹尼克·安·多雷斯坦</dc:creator><dc:date>2023-11-08</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>回复：C 反应蛋白与已确诊心血管疾病患者的心力衰竭：来自英国生物银行的证据</dc:title><dc:identifier>下午：37940237</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.09.803</dc:identifier></item><item><title> C 反应蛋白与患有心血管疾病的患者心力衰竭：来自英国生物银行的证据</title><link/>https://pubmed.ncbi.nlm.nih.gov/37940236/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231109170741&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 11 月 14 日；82(20):e191-e192.doi:10.1016/j.jacc.2023.08.052。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37940236/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231109170741&v=2.17.9.post6+86293ac">37940236</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.08.052>10.1016/j.jacc.2023.08.052</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37940236</guid><pubDate> Wed, 08 Nov 2023 06:00:00 -0500</pubDate><dc:creator>雅库布·莫尔兹</dc:creator><dc:creator>安德烈·林凯维奇</dc:creator><dc:date>2023-11-08</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>C 反应蛋白与患有心血管疾病的患者心力衰竭：来自英国生物银行的证据</dc:title><dc:identifier>下午:37940236</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.052</dc:identifier></item><item><title>自身免疫性疾病患者心房颤动的长期发病率</title><link/>https://pubmed.ncbi.nlm.nih.gov/37940235/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231109170741&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 11 月 14 日；82(20):1969-1971.doi:10.1016/j.jacc.2023.09.802。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37940235/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231109170741&v=2.17.9.post6+86293ac">37940235</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.09.802>10.1016/j.jacc.2023.09.802</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37940235</guid><pubDate> Wed, 08 Nov 2023 06:00:00 -0500</pubDate><dc:creator>孙国立</dc:creator><dc:creator>奥莱·阿勒霍夫</dc:creator><dc:creator>埃米尔·L·福斯波尔</dc:creator><dc:creator>莫滕·舒</dc:creator><dc:creator>米克尔·林冠</dc:creator><dc:creator>杰斯珀·哈斯楚普·斯文森</dc:creator><dc:creator>拉斯·科伯</dc:creator><dc:creator>贾瓦德·H·巴特</dc:creator><dc:date>2023-11-08</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>自身免疫性疾病患者心房颤动的长期发病率</dc:title><dc:identifier>下午：37940235</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.09.802</dc:identifier></item><item><title>会员参与是改变全民心血管护理的关键</title><link/>https://pubmed.ncbi.nlm.nih.gov/37940234/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231109170741&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 11 月 14 日；82(20):1967-1968.doi:10.1016/j.jacc.2023.09.820。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37940234/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231109170741&v=2.17.9.post6+86293ac">37940234</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.09.820>10.1016/j.jacc.2023.09.820</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37940234</guid><pubDate> Wed, 08 Nov 2023 06:00:00 -0500</pubDate><dc:creator> B哈德利·威尔逊</dc:creator><dc:creator>凯瑟琳·比加</dc:creator><dc:creator>约瑟夫·E·马林</dc:creator><dc:date>2023-11-08</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>会员参与是改变全民心血管护理的关键</dc:title><dc:identifier>下午：37940234</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.09.820</dc:identifier></item><item><title>评估成人慢性主动脉瓣反流的影像学方法：JACC 最先进的综述</title><link/>https://pubmed.ncbi.nlm.nih.gov/37940233/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231109170741&amp;v=2.17.9.post6+86293ac<description>召开了一次全球多学科研讨会，讨论主动脉瓣反流 (AR) 的多模式诊断评估。具体来说，重点是 AR 严重程度的评估工具，并分析有关主动脉瓣介入最佳时机的不断变化的数据。该专家小组的关键概念总结为：1) 超声心动图是评估 AR 严重程度的主要成像方式；然而，当数据不一致或不完整时，心脏磁共振可能... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 11 月 14 日；82(20):1953-1966.doi:10.1016/j.jacc.2023.08.051。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">召开了一次全球多学科研讨会，讨论主动脉瓣反流 (AR) 的多模式诊断评估。具体来说，重点是 AR 严重程度的评估工具，并分析有关主动脉瓣介入最佳时机的不断变化的数据。该专家小组的关键概念概括为：1）超声心动图是评估 AR 严重程度的主要成像方式；然而，当数据不一致或不完整时，心脏磁共振可能会有所帮助；2）左心室大小和功能的评估对于确定 AR 的时机至关重要干预；3) 最近的证据表明，目前对无症状严重 AR 患者进行干预的切点需要进一步审查；4) 左心室收缩末期容积指数已成为一个额外参数，有望指导干预时机；5)其他因素（包括整体纵向应变、反流分数和心肌细胞外容量）值得未来研究。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37940233/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231109170741&v=2.17.9.post6+86293ac">37940233</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.08.051>10.1016/j.jacc.2023.08.051</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37940233</guid><pubDate> Wed, 08 Nov 2023 06:00:00 -0500</pubDate><dc:creator>劳伦·拉纳德</dc:creator><dc:creator>罗伯特·奥博诺</dc:creator><dc:creator>里克·西村</dc:creator><dc:creator>迈克尔·J·麦克</dc:creator><dc:creator>维诺德·H·图拉尼</dc:creator><dc:creator>约瑟夫·巴伐利亚</dc:creator><dc:creator>帕特里克·T·奥加拉</dc:creator><dc:creator>杰伦·J·巴克斯</dc:creator><dc:creator>菲利普·布兰克</dc:creator><dc:creator>维多利亚·德尔加多</dc:creator><dc:creator>乔纳森·莱普西克</dc:creator><dc:creator>罗伯托·M·朗</dc:creator><dc:creator>赫克托一世·米凯莱娜</dc:creator><dc:creator>若昂·L·卡瓦尔坎特</dc:creator><dc:creator>托斯顿·P·瓦尔</dc:creator><dc:creator>马丁·B·莱昂</dc:creator><dc:creator>维拉·H·里戈林</dc:creator><dc:creator>心脏瓣膜合作社</dc:creator><dc:date>2023-11-08</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>评估成人慢性主动脉瓣反流的影像学方法：JACC 最先进的综述</dc:title><dc:identifier>下午:37940233</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.051</dc:identifier></item><item><title>基于深度学习的超声心动图解读的新希望：您正在寻找的 DROID</title><link/> https://pubmed.ncbi.nlm.nih.gov/37940232/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231109170741&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 11 月 14 日；82(20):1949-1952.doi:10.1016/j.jacc.2023.09.799。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37940232/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231109170741&v=2.17.9.post6+86293ac">37940232</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.09.799>10.1016/j.jacc.2023.09.799</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37940232</guid><pubDate> Wed, 08 Nov 2023 06:00:00 -0500</pubDate><dc:creator>马顿·托科迪</dc:creator><dc:creator>阿提拉·科瓦奇</dc:creator><dc:date>2023-11-08</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>基于深度学习的超声心动图解读的新希望：您正在寻找的 DROID</dc:title><dc:identifier>下午：37940232</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.09.799</dc:identifier></item><item><title>通过深度学习评估左心结构和功能可预测心血管结果</title><link/>https://pubmed.ncbi.nlm.nih.gov/37940231/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231109170741&amp;v=2.17.9.post6+86293ac<description>结论：深度学习超声心动图解读准确地量化了左心结构和功能的标准测量，这反过来又与未来的临床结果相关。深度学习可以实现大规模的自动超声心动图解读和疾病预测。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 11 月 14 日；82(20):1936-1948.doi:10.1016/j.jacc.2023.09.800。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：超声心动图图像的深度学习解释可能有助于心脏结构和功能的自动评估。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：我们开发了一种深度学习模型来解释超声心动图，并检查深度学习衍生的超声心动图测量与事件结果的关联。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们训练并验证了一个 3 维卷积神经网络模型，用于超声心动图视图分类和左心房尺寸、左心室壁厚度、心室直径和射血分数的量化。训练样本包括来自 64,028 个超声心动图（n = 27,135）。回顾性多机构动态心脏病学电子健康记录样本。在单独的纵向初级保健样本和外部医疗保健系统数据集中进行验证。Cox 模型评估了模型衍生的左心测量与事件结果的关联。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：深度学习区分超声心动图视图（胸骨旁长轴、心尖 4 腔和心尖 2 腔视图与人类专家注释的接收器操作曲线下面积 >;0.97）和量化标准左心测量（R <sup>2</sup>范围 = 0.53 至0.91 vs 研究报告值）。模型性能在 2 个外部验证样本中相似。模型衍生的左心测量可预测心力衰竭、心房颤动、心肌梗塞和死亡事件。1-SD 较低的模型左心室射血分数相关心力衰竭的风险增加 43%（HR：1.43；95% CI：1.23-1.66），死亡风险增加 17%（HR：1.17；95% CI：1.06-1.30）。其他模型也观察到类似的结果 -得出左心测量值。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：深度学习超声心动图解读准确地量化了左心结构和功能的标准测量，这反过来又与未来的临床结果相关。深度学习可以实现大规模的自动超声心动图解读和疾病预测。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37940231/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231109170741&v=2.17.9.post6+86293ac">37940231</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.09.800>10.1016/j.jacc.2023.09.800</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37940231</guid><pubDate> Wed, 08 Nov 2023 06:00:00 -0500</pubDate><dc:creator>刘艾米莉</dc:creator><dc:creator>保罗·迪·阿奇勒</dc:creator><dc:creator>卡维亚·科帕拉普</dc:creator><dc:creator>卡尔·T·安德鲁斯</dc:creator><dc:creator>普尔基特·辛格</dc:creator><dc:creator>克里斯托弗·里德</dc:creator><dc:creator>穆斯塔法·阿鲁西</dc:creator><dc:creator>沙恩·库希德</dc:creator><dc:creator>朱利安·S·海莫维奇</dc:creator><dc:creator>帕特里克·埃利诺</dc:creator><dc:creator>迈克尔·H·皮卡德</dc:creator><dc:creator>普尼特·巴特拉</dc:creator><dc:creator>史蒂文·卢比茨</dc:creator><dc:creator>詹妮弗·E·何</dc:creator><dc:date>2023-11-08</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>通过深度学习评估左心结构和功能可预测心血管结果</dc:title><dc:identifier>下午:37940231</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.09.800</dc:identifier></item><item><title>加速药物开发的多组学见解：他们会兑现承诺吗？</title><link/> https://pubmed.ncbi.nlm.nih.gov/37940230/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231109170741&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 11 月 14 日；82(20):1932-1935.doi:10.1016/j.jacc.2023.09.801。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37940230/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231109170741&v=2.17.9.post6+86293ac">37940230</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.09.801>10.1016/j.jacc.2023.09.801</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37940230</guid><pubDate> Wed, 08 Nov 2023 06:00:00 -0500</pubDate><dc:creator>邓伟豪</dc:creator><dc:creator>沃尔夫冈·柯尼希</dc:creator><dc:date>2023-11-08</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>加速药物开发的多组学见解：他们会兑现承诺吗？</dc:title><dc:identifier>下午:37940230</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.09.801</dc:identifier></item><item><title>多组学分析提供了与心力衰竭进展相关的新途径</title><link/>https://pubmed.ncbi.nlm.nih.gov/37940229/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231109170741&amp;v=2.17.9.post6+86293ac<description>结论：整合基因组、转录组和蛋白质组数据的系统生物学方法确定了与死亡率相关的 4 条主要途径。这些途径与心脏保护性 ERBB2 受体的激活减少有关，而这种受体可以通过神经调节蛋白进行修饰。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 11 月 14 日；82(20):1921-1931.doi:10.1016/j.jacc.2023.08.053。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：尽管心力衰竭患者的药物治疗取得了重大进展，但残余死亡率仍然很高，这表明当前心力衰竭治疗尚未针对重要途径。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：我们寻求整合大量心力衰竭患者的遗传、转录组和蛋白质组数据，以检测与心力衰竭进展导致死亡相关的主要途径。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们使用基于堆叠泛化框架和梯度增强算法的机器学习方法，使用 54 种临床表型、403 种循环血浆蛋白、全血中的 36,046 个转录物表达水平和 600 万个基因组标记来模拟 2,516 名患有糖尿病的患者的全因死亡率。来自 BIOSTAT-CHF（慢性心力衰竭定制治疗的系统生物学研究）研究的心力衰竭。结果在 1,738 名患者的独立队列中得到验证。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：患者平均年龄为 70 岁（Q1-Q3：61-78 岁），27% 为女性，N 端 B 型利钠肽前体中位数为 4,275 ng/L（Q1-Q3：2,360- 8,486 ng/L)，7% 患有射血分数保留的心力衰竭。在中位随访 21 个月期间，657 名 (26%) 患者死亡。与全因死亡率显着相关的 4 个主要途径是：1) PI3K/Akt 通路；2) MAPK 通路；3) Ras 信号通路；4) 表皮生长因子受体酪氨酸激酶抑制剂耐药性。结果在 1,738 名患者的独立队列中得到验证。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：整合基因组、转录组和蛋白质组数据的系统生物学方法确定了与死亡率相关的 4 条主要途径。这些途径与心脏保护性 ERBB2 受体的激活减少有关，而这种受体可以通过神经调节蛋白进行修饰。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37940229/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231109170741&v=2.17.9.post6+86293ac">37940229</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.08.053>10.1016/j.jacc.2023.08.053</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37940229</guid><pubDate> Wed, 08 Nov 2023 06:00:00 -0500</pubDate><dc:creator>沃特奥沃科克</dc:creator><dc:creator>若昂·P·贝洛·佩雷拉</dc:creator><dc:creator>特洛伊·马斯兰</dc:creator><dc:creator>约翰娜·E·埃门斯</dc:creator><dc:creator>西尔维亚·M·菲格斯卡</dc:creator><dc:creator>贾斯帕·特罗普</dc:creator><dc:creator>安德里亚·L·科克莫尔</dc:creator><dc:creator>克里斯托弗·P·纳尔逊</dc:creator><dc:creator>明图·纳斯</dc:creator><dc:creator>西蒙·PR·罗曼</dc:creator><dc:creator>约翰·GF·克莱兰</dc:creator><dc:creator>法伊兹·赞纳德</dc:creator><dc:creator>德克·J·范·维尔德豪森</dc:creator><dc:creator>詹志朗</dc:creator><dc:creator>彼得·波尼科夫斯基</dc:creator><dc:creator>格拉西莫斯·菲利帕托斯</dc:creator><dc:creator>斯特凡·安克</dc:creator><dc:creator>马可·梅特拉</dc:creator><dc:creator>肯尼思·迪克斯坦</dc:creator><dc:creator>梁良伍</dc:creator><dc:creator>鲁道夫·德波尔</dc:creator><dc:creator>纳塔尔·范瑞尔</dc:creator><dc:creator>马克斯·尼乌多普</dc:creator><dc:creator>阿尔伯特·K·格罗恩</dc:creator><dc:creator>埃里克·斯特罗斯</dc:creator><dc:creator>艾尔科·茨温德曼</dc:creator><dc:creator>尼尔什·J·萨马尼</dc:creator><dc:creator>卡罗琳·SP·林</dc:creator><dc:creator>叶夫根尼·莱文</dc:creator><dc:creator>阿德里安·沃尔斯</dc:creator><dc:date>2023-11-08</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>多组学分析提供了与心力衰竭进展相关的新途径</dc:title><dc:identifier>下午:37940229</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.053</dc:identifier></item><item><title>血浆蛋白质组学鉴定缺血性心脏病的药物靶点</title><link/>https://pubmed.ncbi.nlm.nih.gov/37940228/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231109170741&amp;v=2.17.9.post6+86293ac<description>结论：对中国和欧洲成年人的蛋白质组和遗传数据进行综合分析，为 FURIN 和多种其他蛋白质作为治疗 IHD 的潜在新药物靶点提供了因果支持。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 11 月 14 日；82(20):1906-1920.doi:10.1016/j.jacc.2023.09.804。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：前瞻性研究中血浆蛋白质组和遗传标记的综合分析可以阐明蛋白质的因果相关性，并发现缺血性心脏病（IHD）和其他疾病的新靶标。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：本研究的目的是在人群研究中检查蛋白质组学和遗传学数据与 IHD 的关联，以发现新的预防治疗方法。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们在中国嘉道理生物库 (CKB) 中进行了一项巢式病例队列研究，涉及 1,971 例 IHD 病例和 2,001 名亚队列参与者，这些参与者均经过基因分型且既往无心血管疾病。我们使用 OLINK EXPLORE 测量了存储的基线样本中的 1,463 种蛋白质。小组。在考虑了多重测试后，Cox 回归产生了与单个蛋白质相关的 IHD 的调整 HR。此外，在 CKB 和 UK Biobank 的全基因组关联研究中为蛋白质鉴定的顺式蛋白质定量基因座 (pQTL) 被用作工具变量涉及全球 CARDIOGRAM+C4D 联盟的独立 2 样本孟德尔随机化 (MR) 研究（210,842 例 IHD 病例和 1,378,170 例对照）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：总共 361 个蛋白质在 CKB 中以错误发现率 &lt;0.05 与 IHD 风险显着相关（349 个正向，12 个负向），其中包括脑钠肽 N 末端激素原和前蛋白转化酶枯草杆菌蛋白酶/kexin 9 型。在这 361 个蛋白质中, 212 个在 CKB 中具有顺式 pQTL，并且对 CARDIOGRAM+C4D 中的 198 个变体进行 MR 分析，鉴定出 13 个蛋白质，这些蛋白质显示出与 IHD 的潜在因果关系。对欧洲人中鉴定的 307 个顺式 pQTL 进行独立 MR 分析，复制了 4 种蛋白酶（FURIN、蛋白酶）的关联。 -激活受体-1、Asialo糖蛋白受体-1和基质金属蛋白酶-3)。进一步的下游分析表明，在内皮细胞中高表达的FURIN是一个潜在的新靶点，基质金属蛋白酶-3是IHD的潜在再利用靶点。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：对中国和欧洲成年人的蛋白质组和遗传数据进行综合分析，为 FURIN 和多种其他蛋白质作为治疗 IHD 的潜在新药物靶点提供了因果支持。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37940228/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231109170741&v=2.17.9.post6+86293ac">37940228</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.09.804>10.1016/j.jacc.2023.09.804</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37940228</guid><pubDate> Wed, 08 Nov 2023 06:00:00 -0500</pubDate><dc:creator>莫森·马齐迪</dc:creator><dc:creator>尼尔·赖特</dc:creator><dc:creator>庞耀</dc:creator><dc:creator>克里斯蒂娜·卡尔索纳基</dc:creator><dc:creator>爱奥娜·米尔伍德</dc:creator><dc:creator>汉娜·弗莱</dc:creator><dc:creator>萨雷多·赛义德</dc:creator><dc:creator>阿尔弗雷德·波扎里基</dc:creator><dc:creator>佩佩</dc:creator><dc:creator>陈一平</dc:creator><dc:creator>丹尼尔·艾弗里</dc:creator><dc:creator>杜怀东</dc:creator><dc:creator>丹·瓦莱·施密特</dc:creator><dc:creator>杨凌</dc:creator><dc:creator>吕军</dc:creator><dc:creator>于灿庆</dc:creator><dc:creator>陈俊石</dc:creator><dc:creator>迈克尔·希尔</dc:creator><dc:creator>迈克尔·V·霍姆斯</dc:creator><dc:creator>乔安娜·MM·豪森</dc:creator><dc:creator>理查德·皮托</dc:creator><dc:creator>罗里·柯林斯</dc:creator><dc:creator>德里克·贝内特</dc:creator><dc:creator>罗宾·沃尔特斯</dc:creator><dc:creator>李黎明</dc:creator><dc:creator>罗伯特·克拉克</dc:creator><dc:creator>Zhengming Chen</dc:creator><dc:creator> China Kadoorie Biobank Collaborative Group</dc:creator><dc:date> 2023-11-08</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Plasma Proteomics to Identify Drug Targets for Ischemic Heart Disease</dc:title><dc:identifier> pmid:37940228</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.09.804</dc:identifier></item><item><title> Platelet biology and function: plaque erosion vs. rupture</title><link/> https://pubmed.ncbi.nlm.nih.gov/37940193/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231109170741&amp;v=2.17.9.post6+86293ac<description> The leading cause of heart disease in developed countries is coronary atherosclerosis, which is not simply a result of ageing but a chronic inflammatory process that can lead to acute clinical events upon atherosclerotic plaque rupture or erosion and arterial thrombus formation. The composition and location of atherosclerotic plaques determine the phenotype of the lesion and whether it is more likely to rupture or to erode. Although plaque rupture and erosion both initiate platelet activation on... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Nov 6:ehad720. doi: 10.1093/eurheartj/ehad720. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> The leading cause of heart disease in developed countries is coronary atherosclerosis, which is not simply a result of ageing but a chronic inflammatory process that can lead to acute clinical events upon atherosclerotic plaque rupture or erosion and arterial thrombus formation. The composition and location of atherosclerotic plaques determine the phenotype of the lesion and whether it is more likely to rupture or to erode. Although plaque rupture and erosion both initiate platelet activation on the exposed vascular surface, the contribution of platelets to thrombus formation differs between the two phenotypes. In this review, plaque phenotype is discussed in relation to thrombus composition, and an overview of important mediators (haemodynamics, matrix components, and soluble factors) in plaque-induced platelet activation is given. As thrombus formation on disrupted plaques does not necessarily result in complete vessel occlusion, plaque healing can occur. Therefore, the latest findings on plaque healing and the potential role of platelets in this process are summarized. Finally, the clinical need for more effective antithrombotic agents is highlighted.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37940193/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231109170741&v=2.17.9.post6+86293ac">37940193</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad720>10.1093/eurheartj/ehad720</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37940193</guid><pubDate> Wed, 08 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Constance CFMJ Baaten</dc:creator><dc:creator> Magdolna Nagy</dc:creator><dc:creator> Wolfgang Bergmeier</dc:creator><dc:creator> Henri MH Spronk</dc:creator><dc:creator> Paola EJ van der Meijden</dc:creator><dc:date> 2023-11-08</dc:date><dc:source> European heart journal</dc:source><dc:title> Platelet biology and function: plaque erosion vs. rupture</dc:title><dc:identifier> pmid:37940193</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad720</dc:identifier></item><item><title> Growth of the Neo-Aortic Root and Prognosis of Transposition of the Great Arteries</title><link/> https://pubmed.ncbi.nlm.nih.gov/37939977/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231109170741&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: Longitudinal surveillance of the neo-aortic root is warranted long after the ASO. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Oct 31:S0735-1097(23)07874-9. doi: 10.1016/j.jacc.2023.10.023. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Neo-aortic root dilatation can lead to significant late morbidity after the arterial switch operation (ASO) for dextro-transposition of the great arteries (d-TGA). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVES: We sought to examine the growth of the neo-aortic root in d-TGA. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: A single-center, retrospective cohort study of patients that underwent the ASO from 07/1981-09/2022 was performed. Morphology was categorized as d-TGA with intact ventricular septum (d-TGA-IVS), d-TGA with ventricular septal defect (d-TGA-VSD), and double-outlet right ventricle-TGA type (DORV-TGA). Echocardiographically-determined diameters and derived z-scores were measured at the annulus, sinus of Valsalva (SoV), and sinotubular junction (STJ) immediately before the ASO and throughout follow-up. Trends in root dimensions over time were assessed using linear mixed-effects models. The association between intrinsic morphology and the composite of moderate-severe aortic regurgitation (AR) and neo-aortic valve or root reintervention was evaluated with uni- and multivariable Cox proportional hazards models. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Of 1359 patients that underwent the ASO, 593 (44%), 666 (49%), and 100 (7%) patients had d-TGA-IVS, d-TGA-VSD, and DORV-TGA, respectively. Each patient underwent a median of 5 (IQR 3-10) echocardiograms over a median follow-up of 8.6 years (range 0.1-39.3 years). At 30 years, DORV-TGA patients demonstrated greater annular (p&lt;0.001), SoV (p=0.039), and STJ (p=0.041) dilatation relative to d-TGA-IVS patients. On multivariable analysis, intrinsic anatomy, older age at ASO, at least mild AR at baseline, and high-risk root dilatation were associated with moderate-severe AR and neo-aortic valve or root reintervention at late follow-up (all p&lt;0.05). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Longitudinal surveillance of the neo-aortic root is warranted long after the ASO.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37939977/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231109170741&v=2.17.9.post6+86293ac">37939977</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.10.023>10.1016/j.jacc.2023.10.023</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37939977</guid><pubDate> Wed, 08 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Aditya Sengupta</dc:creator><dc:creator> Chrystalle Katte Carreon</dc:creator><dc:creator> Kimberlee Gauvreau</dc:creator><dc:creator> Ji M Lee</dc:creator><dc:creator> Stephen P Sanders</dc:creator><dc:creator> Steven D Colan</dc:creator><dc:creator> Pedro J Del Nido</dc:creator><dc:creator> John E Mayer</dc:creator><dc:creator> Meena Nathan</dc:creator><dc:date> 2023-11-08</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Growth of the Neo-Aortic Root and Prognosis of Transposition of the Great Arteries</dc:title><dc:identifier> pmid:37939977</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.10.023</dc:identifier></item><item><title> The neo-aortic root after arterial switch operation: Defining the new normal</title><link/> https://pubmed.ncbi.nlm.nih.gov/37939976/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231109170741&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Oct 30:S0735-1097(23)07917-2. doi: 10.1016/j.jacc.2023.10.024. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37939976/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231109170741&v=2.17.9.post6+86293ac">37939976</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.10.024>10.1016/j.jacc.2023.10.024</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37939976</guid><pubDate> Wed, 08 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Michael D Seckeler</dc:creator><dc:date> 2023-11-08</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> The neo-aortic root after arterial switch operation: Defining the new normal</dc:title><dc:identifier> pmid:37939976</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.10.024</dc:identifier></item><item><title> Amiodarone and pulmonary toxicity in atrial fibrillation: a nationwide Israeli study</title><link/> https://pubmed.ncbi.nlm.nih.gov/37939798/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231109170741&amp;v=2.17.9.post6+86293ac<description> CONCLUSION: In a contemporary AF population, low-dose amiodarone was associated with a trend towards increased risk of ILD (15%-45%) but a clinically negligible change in absolute risk (maximum of 1.8%), no increased risk of PLC, and a lower risk of all-cause mortality. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Nov 6:ehad726. doi: 10.1093/eurheartj/ehad726. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND AND AIMS: Amiodarone-related interstitial lung disease (ILD) is the most severe adverse effect of amiodarone treatment. Most data on amiodarone-related ILD are derived from periods when amiodarone was given at higher doses than currently used. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: A nationwide population-based study was conducted among patients with incident atrial fibrillation (AF) between 1 December 1999 and 31 December 31 2021. Amiodarone-exposed patients were matched 1:1 with controls unexposed to amiodarone based on age, sex, ethnicity, and AF diagnosis duration. The final patient cohort included only matched pairs where amiodarone therapy was consistent throughout follow-up. Directed acyclic graphs and inverse probability treatment weighting (IPTW) modelling were used. Patients with either prior ILD or primary lung cancer (PLC) were excluded. The primary outcome was the incidence of any ILD. Secondary endpoints were death and PLC. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: The final cohort included 6039 amiodarone-exposed patients who were matched with unexposed controls. The median age was 73.3 years, and 51.6% were women. After a mean follow-up of 4.2 years, ILD occurred in 242 (2.0%) patients. After IPTW, amiodarone exposure was not significantly associated with ILD [hazard ratio (HR): 1.45, 95% confidence interval (CI): 0.97, 2.44, P = 0.09]. There was a trivial higher relative risk of ILD among amiodarone-exposed patients between Years 2 and 8 of follow-up [maximal risk ratio (RR): 1.019]. Primary lung cancer occurred in 97 (0.8%) patients. After IPTW, amiodarone was not associated with PLC (HR: 1.18, 95% CI: 0.76, 2.08, P = 0.53). All-cause death occurred in 2185 (18.1%) patients. After IPTW, amiodarone was associated with reduced mortality risk (HR: 0.65, 95% CI: 0.60, 0.72, P &lt; 0.001). The results were consistent across a variety of sensitivity analyses. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSION: In a contemporary AF population, low-dose amiodarone was associated with a trend towards increased risk of ILD (15%-45%) but a clinically negligible change in absolute risk (maximum of 1.8%), no increased risk of PLC, and a lower risk of all-cause mortality.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37939798/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231109170741&v=2.17.9.post6+86293ac">37939798</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad726>10.1093/eurheartj/ehad726</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37939798</guid><pubDate> Wed, 08 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Gal Tsaban</dc:creator><dc:creator> Daniel Ostrovsky</dc:creator><dc:creator> Hilmi Alnsasra</dc:creator><dc:creator> Nitzan Burrack</dc:creator><dc:creator> Michal Gordon</dc:creator><dc:creator> Amit Shira Babayev</dc:creator><dc:creator> Yara Omari</dc:creator><dc:creator> Louise Kezerle</dc:creator><dc:creator> David Shamia</dc:creator><dc:creator> Sergey Bereza</dc:creator><dc:creator> Yuval Konstantino</dc:creator><dc:creator> Moti Haim</dc:creator><dc:date> 2023-11-08</dc:date><dc:source> European heart journal</dc:source><dc:title> Amiodarone and pulmonary toxicity in atrial fibrillation: a nationwide Israeli study</dc:title><dc:identifier> pmid:37939798</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad726</dc:identifier></item><item><title> Post-translational modifications upon mitochondrial dysfunction in heart failure</title><link/> https://pubmed.ncbi.nlm.nih.gov/37939789/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231109170741&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Nov 6:ehad710. doi: 10.1093/eurheartj/ehad710. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37939789/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231109170741&v=2.17.9.post6+86293ac">37939789</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad710>10.1093/eurheartj/ehad710</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37939789</guid><pubDate> Wed, 08 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Joost PG Sluijter</dc:creator><dc:creator> Junjie Xiao</dc:creator><dc:date> 2023-11-08</dc:date><dc:source> European heart journal</dc:source><dc:title> Post-translational modifications upon mitochondrial dysfunction in heart failure</dc:title><dc:identifier> pmid:37939789</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad710</dc:identifier></item><item><title> Long-Term Clinical and Echocardiographic Outcomes Following the Ross Procedure: A Post Hoc Analysis of a Randomized Clinical Trial</title><link/> https://pubmed.ncbi.nlm.nih.gov/37938855/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231109170741&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS AND RELEVANCE: This study found that the Ross procedure provided excellent survival into the third decade postoperatively that was comparable to that in the general population. Long-term freedom from reintervention demonstrated that the Ross procedure may be a durable substitute into late adulthood, showing a delayed but progressive functional decline. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 Nov 8. doi: 10.1001/jamacardio.2023.4090. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> IMPORTANCE: The Ross procedure as treatment for adults with aortic valve disease (AVD) has been the subject of renewed interest. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVE: To evaluate the long-term clinical and echocardiographic outcomes following the Ross procedure for the treatment of adults with AVD. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> DESIGN, SETTING, AND PARTICIPANTS: This post hoc analysis of a randomized clinical trial included adult patients (age &lt;69 years) who underwent a Ross procedure for the treatment of AVD, including those with active endocarditis, rheumatic AVD, decreased ejection fraction, and previous cardiac surgery. The trial, conducted from September 1, 1994, to May 31, 2001, compared homograft root replacement with the Ross procedure at a single center. Data after 2010 were collected retrospectively in November and December 2022. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> EXPOSURE: Ross procedure. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> MAIN OUTCOMES AND MEASURES: The primary end point was long-term survival among patients who underwent the Ross procedure compared with that in the age-, country of origin- and sex-matched general population. Secondary end points were freedom from any reintervention, autograft reintervention, or homograft reintervention and time-related valve function, autograft diameter, and functional status. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: This study included 108 adults (92 [85%] male) with a median age of 38 years (range, 19-66 years). Median duration of clinical follow-up was 24.1 years (IQR, 22.6-26.1 years; 2488 patient-years), with 98% follow-up completeness. Of these patients, 9 (8%) had active endocarditis and 45 (42%) underwent reoperations. The main hemodynamic lesion was stenosis in 30 (28%) and regurgitation in 49 (45%). There was 1 perioperative death (0.9%). Twenty-five year survival was 83.0% (95% CI, 75.5%-91.2%), representing a relative survival of 99.1% (95% CI, 91.8%-100%) compared with the general population (83.7%). At 25 years, freedom from any reintervention was 71.1% (95% CI, 61.6%-82.0%); from autograft reintervention, 80.3% (95% CI, 71.9%-89.6%); and from homograft reintervention, 86.3% (95% CI, 79.0%-94.3%). Thirty-day mortality after the first Ross-related reintervention was 0% and after all Ross-related reinterventions was 3.8% (n = 1); 10-year survival after reoperation was 96.2% (95% CI, 89.0%-100%). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS AND RELEVANCE: This study found that the Ross procedure provided excellent survival into the third decade postoperatively that was comparable to that in the general population. Long-term freedom from reintervention demonstrated that the Ross procedure may be a durable substitute into late adulthood, showing a delayed but progressive functional decline. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN03530985.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37938855/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231109170741&v=2.17.9.post6+86293ac">37938855</a> | DOI: <a href=https://doi.org/10.1001/jamacardio.2023.4090>10.1001/jamacardio.2023.4090</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37938855</guid><pubDate> Wed, 08 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Maximiliaan L Notenboom</dc:creator><dc:creator> Giovanni Melina</dc:creator><dc:creator> Kevin M Veen</dc:creator><dc:creator> Fabio De Robertis</dc:creator><dc:creator> Giuditta Coppola</dc:creator><dc:creator> Paolo De Siena</dc:creator><dc:creator> Emiliano M Navarra</dc:creator><dc:creator> Jullien Gaer</dc:creator><dc:creator> Michael EK Ibrahim</dc:creator><dc:creator> Ismail El-Hamamsy</dc:creator><dc:creator> Johanna JM Takkenberg</dc:creator><dc:creator> Magdi H Yacoub</dc:creator><dc:date> 2023-11-08</dc:date><dc:source> JAMA cardiology</dc:source><dc:title> Long-Term Clinical and Echocardiographic Outcomes Following the Ross Procedure: A Post Hoc Analysis of a Randomized Clinical Trial</dc:title><dc:identifier> pmid:37938855</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.4090</dc:identifier></item></channel></rss>